Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development

Litten, Raye Z.

doi:10.1111/acer.13222

Cited by 3 publications

References 55 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Advances in Pharmacotherapy Development: Human Clinical Studies

Litten

Falk

Ryan

et al. 2017

The Neuropharmacology of Alcohol

View full text Add to dashboard Cite

For more than 25 years, researchers have made advances in developing medications to treat alcohol use disorder (AUD), highlighted by the US Food and Drug Administration's (FDA's) approval of disulfiram, naltrexone (oral and long-acting), and acamprosate. These medications are also approved in Europe, where the European Medicines Agency (EMA) recently added a fourth medication, nalmefene, for AUD. Despite these advances, today's medications have a small effect size, showing efficacy for only a limited number of individuals with AUD. However, a host of new medications, which act on variety of pharmacologic targets, are in the pipeline and have been evaluated in numerous human studies. This article reviews the efficacy and safety of medications currently being tested in human trials and looks at ongoing efforts to identify candidate compounds in human studies. As mentioned in the National Institute on Alcohol Abuse and Alcoholism's Strategic Plan 2017-2021 ( https://www.niaaa.nih.gov/sites/default/files/StrategicPlan_NIAAA_optimized_2017-2020.pdf ), medications development remains a high priority. By developing more effective and safe medications, and identifying those patients who will benefit the most from these treatments, we can provide clinicians with the tools they need to treat this devastating disorder, providing relief for patients and their families and markedly improving public health and safety.

show abstract